Configuring the Productive Assets of International Pharmaceutical Firms: New Corporate Strategies
The aim of the research is to build the conceptual models proposed in the literature and compare them with the choices made by the laboratories in terms of localization of R & D and production centers. From an empirical investigation of the approaches used by major laboratories (annual reports, press releases) we propose to provide explanations for the reasons behind investments by pharmaceutical laboratories. In a second part, we seek to understand where laboratories are trying to locate their productive assets to obtain the best performance. We take a dual approach: From a dissection of the concept of "geographic scope" into two components, we seek to identify laboratory practices. Then we try to identify strategies for international plant configurations. Finally, we use the matrix developed by Rugman to assess the strategies developed by the pharmaceutical laboratories.
|Date of creation:||2011|
|Date of revision:||2011|
|Contact details of provider:|| Postal: Pôle Lorrain de Gestion, 13 rue Michel Ney, 54 000 Nancy|
Web page: http://repec.cerefige.univ-lorraine.fr
More information through EDIRC
When requesting a correction, please mention this item's handle: RePEc:fie:wpaper:1116. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Sebastien Liarte)
If references are entirely missing, you can add them using this form.